Table 2.
Effectiveness of adalimumab at week 12 in patients with ankylosing spondylitis by subgroup of enthesitis or peripheral arthritis or both
| No enthesitis + no arthritis (n = 457) |
Enthesitis + no arthritis (n = 512) |
Arthritis + no enthesitis (n = 107) |
Enthesitis + arthritis (n = 174) |
P valuea | |
|---|---|---|---|---|---|
| Median First quartile, third quartile [95% confidence interval] | |||||
| BASDAI, 0 to 10 | |||||
| Baseline | 5.9 4.9, 6.9 |
6.4 5.4, 7.5 |
6.7 5.7, 7.7 |
6.6 5.7, 7.6 |
< 0.001 |
| Week 12 | 2.1 0.8, 4.1 |
2.6 1.1, 5.1 |
3.1 1.5, 4.8 |
2.7 1.2, 5.0 |
|
| Change from baseline to week12 | -3.6 -4.8, -1.7 [-3.8 to -3.3] |
-3.4 -4.9, -1.5 [-3.7 to -3.1] |
-3.1 -5.0, -1.8 [-4.0 to -2.7] |
-3.5 -4.9, -1.7 [-3.7 to -2.9] |
0.813 |
| BASFI, 0 to 10 | |||||
| Baseline | 4.9 3.4, 6.7 |
5.7 4.0, 7.3 |
5.8 3.7, 7.0 |
6.0 4.3, 7.5 |
< 0.001 |
| Week 12 | 2.2 1.0, 4.3 |
2.7 1.0, 5.1 |
3.1 1.4, 5.3 |
2.8 1.3, 5.3 |
|
| Change from baseline to week12 | -1.9 -3.6, -0.7 [-2.1 to -1.7] |
-2.1 -3.8, -0.6 [-2.4 to -1.7] |
-1.8 -3.2, -0.7 [-2.2 to -1.5] |
-1.9 -3.7, -0.5 [-2.2 to -1.5] |
0.828 |
| Patient's Global Assessment of disease activity, 0- to 100-mm visual analog scale | |||||
| Baseline | 67 49, 80 |
71 53, 83 |
72 54, 81 |
72 53, 83 |
0.004 |
| Week 12 | 21 8, 46 |
24 8, 52 |
25 11, 48 |
26 10, 52 |
|
| Change from baseline to week12 | -35 -58, -14 [-40 to -32] |
-38 -59, -15 [-42 to -34] |
-39 -61, -13 [-48 to -26] |
-33 -57, -12 [-41 to -24] |
0.806 |
| C-reactive proteinb, mg/dL | |||||
| Baseline | 1.2 0.6, 2.5 |
1.2 0.5, 2.4 |
1.5 0.8,3.6 |
1.3 0.6, 3.4 |
0.448 |
| Week 12 | 0.4 0.2, 0.8 |
0.4 0.2, 0.8 |
0.6 0.2, 1.5 |
0.4 0.1, 0.9 |
|
| Change from baseline to week12 | -0.7 -2.1, -0.1 [-0.9 to -0.6] |
-0.8 -1.7, -0.2 [-1.0 to -0.7] |
-1.4 -1.7, -0.1 [-1.0 to -0.4] |
-0.7 -2.6, -0.1 [-1.3 to -0.4] |
0.857 |
aP values (two-sided) are based on Jonckheere-Terpstra tests for trends between subgroups without enthesitis and peripheral arthritis, with either enthesitis or peripheral arthritis, and with both. bReference value is 0.4 mg/dL. BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index.